SecBot SecBot
8-K ·Filed Aug 14, 2026

NMRA

Neumora Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001193125-26-350349
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming data readouts for NMRA-511 (Q4 2026) and NMRA-898 (H2 2026) as these are the next major catalysts. Cash runway into Q3 2027 suggests no near-term financing urgency, but the burn rate implies a potential capital raise in 2027 if no partnering or milestone payments materialize.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

NMRA drug pipeline →

NMRA-511

◆ Mixed Named in this 8-K
Impact
Phase
Phase 1b/2a
Time to market
At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials. The drug is still in early clinical development (Phase 1b/2a).
Next catalyst
None dated

What to watchWatch for NMRA-511 MAD expansion cohort data in Q4 2026, positive results could drive a significant rally given the stock's ~$1.04 price and 380% implied analyst upside, but negative data would pressure shares. The company has multiple shots on goal (navacaprant, NMRA-898, NMRA-215), so NMRA-511 is not a single-point-of-failure.

Price Chart

Loading chart...

Executive Summary

Neumora Therapeutics reported Q2 2026 results with a net loss of $43.1M ($0.23 per share), in line with consensus estimates. The company also announced a leadership transition: co-founder Paul Berns becomes Executive Chair, President Joshua Pinto succeeds as CEO, and Doron Sagman joins as CMO. Cash stood at $116.8M, expected to fund operations into Q3 2027. Pipeline timelines remain on track with key data readouts expected in H2 2026.

Key Financial Metrics

EPS
−$0.23
est −$0.23 · 0.0%
Rating
in line

Key Facts

  • Net loss of $43.1M ($0.23 per share) for Q2 2026, in line with consensus of $0.23 loss per share
  • Cash and cash equivalents of $116.8M as of June 30, 2026, down from $182.5M at Dec 31, 2025
  • Leadership transition: Paul Berns becomes Executive Chair, Joshua Pinto appointed CEO and board member, Doron Sagman named CMO
  • NMRA-215 (NLRP3 inhibitor for obesity) expects IND submission in Q4 2026 and Phase 1 start by end of 2026
  • NMRA-511 (AD agitation) MAD expansion cohort data expected Q4 2026; Phase 2 start by end of 2026
  • NMRA-898 (schizophrenia) Phase 1 data expected in H2 2026
  • R&D expense decreased to $29.3M from $38.7M year-over-year; G&A decreased to $12.9M from $15.3M

Financial Impact

No material financial impact; net loss narrowed year-over-year but cash burn continues at ~$33M per quarter

cashnet lossoperating expenses

Risk Factors

  • Cash burn rate of ~$33M per quarter may require financing before Q3 2027
  • Clinical trial risks for navacaprant (KOASTAL) and early-stage pipeline programs
  • No revenue; full dependence on pipeline success and capital markets

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-350349
Document: nmra-20260814.htm0001193125-26-350349
Document: 0001193125-26-350349-index-headers.html0001193125-26-350349
Document: 0001193125-26-350349-index.html0001193125-26-350349
Document: 0001193125-26-350349.txt0001193125-26-350349
8-K Data (Synthetic)0001193125-26-350349

Track record

14 reports on NMRA

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
  3. Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
  5. Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
  6. Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
  7. Aug 14, 202613w ago 8-K Neutral 4/10 Viewing No price data
  8. Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
  9. Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
  10. Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026